Late-Breaking at CROI 2025: SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to Demonstrate Prevention of COVID-19 as Post Exposure Prophylaxis
The study met both the primary endpoint and the key secondary endpoint. The primary analysis population included 2,041 household contact participants with a negative screening SARS-CoV-2 test and excluded those found to already be positive by PCR at the central laboratory. 1 Of the study participants treated with ensitrelvir, 2.9% developed symptomatic COVID-19 compared to 9.0% of participants on placebo (risk ratio: 0.33; 95% CI: 0.22-0.49; p<0.0001) at Day 10, the primary endpoint, representing a 67% relative risk reduction. 1 The secondary analysis population included 2,387 household contact participants who had a negative local test for SARS-CoV-2 but did not exclude those with a central laboratory positive SARS-CoV-2 PCR at baseline. 1 The results were similar to the primary analysis population with 4.4% of participants treated with ensitrelvir developing symptomatic COVID-19 compared to 10.2% of participants on placebo (risk ratio: 0.43; 95% CI: 0.32-0.59; p<0.0001). 1
'COVID-19 remains a major threat to public health, and the best way to avoid the serious and long-term complications associated with the virus is to reduce the risk of being infected in the first place,' said Frederick Hayden, MD, Professor Emeritus of Clinical Virology and Professor Emeritus of Medicine, University of Virginia School of Medicine. 'In addition to vaccination, post-exposure prophylaxis with timely use of an oral antiviral would be a valuable way to help prevent COVID-19 illness in people who have been exposed, especially people at high risk for severe disease.'
Ensitrelvir, known as Xocova ® in countries where it is approved, received emergency regulatory approval in Japan in 2022 and full approval in March 2024 for the treatment of COVID-19. It became available in Singapore via a Special Access Route application in 2023, and it is currently under regulatory review in Taiwan. Ensitrelvir was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) in 2025 for post-exposure prophylaxis of COVID-19 following contact with an individual who has COVID-19. 3 In addition, ensitrelvir was granted Fast Track designation by the U.S. FDA in 2023 for the treatment of COVID-19. Ensitrelvir is an investigational drug outside of Japan and Singapore. In addition, the brand name Xocova ® has not been approved for use outside of Japan and Singapore and pertains only to the approved drug in Japan and Singapore.
SCORPIO-PEP assessed 2,387 study participants aged 12 years and older with a negative screening test for SARS-CoV-2 infection and no symptoms at the time of enrollment, who were exposed to a person living in their household with symptomatic COVID-19. 1 Study participants were randomly assigned in a 1:1 ratio to receive ensitrelvir (125 mg) or placebo, once daily, and began treatment within three days of when the household member with COVID-19 began showing symptoms. 1 Participants then continued ensitrelvir or placebo for five days. 1
Overall, ensitrelvir was generally well tolerated, with similar rates of adverse events in the ensitrelvir group and the placebo group (15.1% and 15.5%, respectively). 1 There were no COVID-19 related hospitalizations or deaths. 1
'SARS-CoV-2 continues to circulate and there are still thousands of hospitalizations and hundreds of COVID-19 deaths each week,' said Simon Portsmouth, MD, FRCP, Senior Vice President, Head of Clinical Development. 'If we can reduce the risk of infection among individuals who are exposed to SARS-CoV-2, this fulfills an important unmet medical need. Oral antivirals have changed the way we treat and prevent other infectious diseases, including influenza and HIV, and there is an opportunity to do the same with COVID-19.'
COVID-19 continues to pose a health risk for many people and remains a public health threat. 4,5 It can impact quality of life, lead to absence from work, cause long COVID, and can progress to severe disease, hospitalizations and death. 4,5 Additional protective options are needed for those who have close contact with people with COVID-19.
Post-exposure prophylaxis (PEP) is needed to reduce the risk of developing the disease after exposure, particularly those at high risk of developing severe illness, such as those with weakened immune systems, chronic health conditions, the elderly or those who could transmit COVID-19 to high-risk populations. 6 In settings like hospitals, nursing homes, or long-term facilities, PEP could help protect against COVID-19 and contain the potential clinical and economic impact. 7,8 PEP may help reduce the risk of developing acute COVID-19, thereby reducing the risk of developing long COVID. 8,9
PEP is also an important preventive option as new variants emerge, which may escape vaccine-induced or infection-acquired immunity. 10 Additionally, low vaccination rates and waning immunity after vaccination call for additional preventative measures. 11
About ensitrelvir
Ensitrelvir is a 3CL protease inhibitor created through joint research between Hokkaido University and Shionogi. SARS-CoV-2 has an enzyme called 3CL protease, which is essential for the replication of the virus. 12 Ensitrelvir suppresses the replication of SARS-CoV-2 by selectively inhibiting the 3CL protease. 12
Shionogi evaluated the safety and efficacy of ensitrelvir through SCORPIO-SR, a Phase 3 study conducted in Asia, during the Omicron-dominant phase of the epidemic. 13 In this study, ensitrelvir showed both clinical symptomatic efficacy (symptom resolution sustained for at least 24 hours) for five typical Omicron-related symptoms (primary endpoint) and antiviral efficacy (key secondary endpoint) in a predominantly vaccinated population of patients with mild-to-moderate SARS-CoV-2 infection, regardless of risk factors. 13 Regarding safety, most adverse events were mild in severity and no deaths were seen in the study. 13 Among the most common treatment-related adverse events were temporary decreases in high-density lipoprotein and increased blood triglycerides, as observed in previous studies. 13 The data from this study were published in JAMA Network Open.
Additionally, the Phase 3 SCORPIO-HR study assessed ensitrelvir in a broad range of symptomatic, non-hospitalized participants with COVID-19, regardless of past SARS-CoV-2 infection. The study did not meet its primary endpoint of a statistically significant reduction in time to sustained resolution (symptom resolution sustained for at least 48 hours) of 15 common COVID-19 related symptoms for once-daily ensitrelvir compared to placebo. 14 No new safety concerns were identified in the study, and treatment with ensitrelvir was well tolerated, with a similar adverse event profile as placebo. 14
An investigator-initiated research study with ensitrelvir is ongoing in hospitalized patients for the management of COVID-19 as part of the Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE) platform protocol. STRIVE was developed under the auspices of NIH's Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership.
Shionogi also recently released preliminary results from a multicenter, randomized, double-blind, placebo-controlled trial of ensitrelvir in mild to moderate COVID-19 patients aged 6 to under 12 years in Japan. The study confirmed safety and tolerability and found the pharmacokinetics of ensitrelvir in this age group similar to adults. 15
Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
* Literature search conducted December 2024.
Reference List:
Hayden F. Ensitrelvir to Prevent COVID-19 in Households: SCORPIO-PEP Phase III Placebo-Controlled Trial Results. Abstract 200. Presented at CROI 2025, San Francisco, CA: March 9-12, 2025.
U.S. Food and Drug Administration. Available at: https://www.fda.gov/search?s=COVID%20post%20exposure%20prophylaxis&sort_bef_combine=rel_DESC&f%5B0%5D=section%3A23692.
U.S. Food and Drug Administration. Fast Track Designation of S-217622 (ensitrelvir).
The changing threat of COVID-19. Centers for Disease Control and Prevention. Accessed February 24, 2025. Available at: https://www.cdc.gov/ncird/whats-new/changing-threat-covid-19.html.
Long COVID Basics. Centers for Disease Control and Prevention. Accessed February 24, 2025. Available at: https://www.cdc.gov/covid/long-term effects/?CDC_AAref_Val=https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html.
Bartoszko JJ, et al. Prophylaxis against covid-19: living systematic review and network meta-analysis. BMJ. 26 Apr 2021;373:n949. doi:10.1136/bmj.n949.
Lee SH, Son H, Peck KR. Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals? Science Direct. 17 Apr 2020;55:6. doi:10.1016/j.ijantimicag.2020.105988.
Gentile I, Maraolo AE, Piscitelli P, Colao A. COVID-19: Time for Post-Exposure Prophylaxis? Int J Environ Res Public Health. 2020 Jun 4;17(11):3997. doi:10.3390/ijerph17113997.
Al-Aly Z, Topol E. Solving the puzzle of Long Covid. Science. 22 Feb 2024; 383:6685,830-832. doiI:10.1126/science.adl0867.
Carabelli AM, Peacock TP, Thorne LG, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nature Reviews Microbiology. 18 Jan 2023;21:162–177. doi:10.1038/s41579-022-00841-7.
Kriss JL, Black CL, Razzaghi H, et al. Influenza, COVID-19, and Respiratory Syncytial Virus Vaccination Coverage Among Adults — United States, Fall 2024. MMWR Morb Mortal Wkly Rep. 21 Nov 2024;73:1044–1051. doi:10.15585/mmwr.mm7346a1.
Unoh Y, et al. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. Journal of Medicinal Chemistry. 30 Mar 2022;65:9,6499-6512. doi:10.1021/acs.jmedchem.2c00117.
Yotsuyanagi H, et al. Efficacy and safety of 5-day oral Ensitrelvir for patients with mild to moderate COVID-19. JAMA Netw Open. 9 Feb 2024;7(2):e2354991. doi:10.1001/jamanetworkopen.2023.54991.
Luetkemeyer A, et al. Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial, Clinical Infectious Diseases, 2025;, ciaf029, https://doi.org/10.1093/cid/ciaf029.
3 rd Quarter of Fiscal 2024 Financial Results. January 31, 2025. Page 20. Accessed March 5, 2025. Available at: .
KEYWORD: JAPAN ASIA PACIFIC
SOURCE: Shionogi USA
Copyright Business Wire 2025.
PUB: 03/12/2025 11:25 AM/DISC: 03/12/2025 11:25 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
2 hours ago
- USA Today
See where COVID cases are rising amid summer wave: New CDC data
New data from the Centers for Disease Control and Prevention shows activity of COVID-19 is increasing across a wide swath of the country. As the U.S. approaches the midpoint of summer, the CDC is reporting cases of the virus are growing or likely growing in more than half of all states, including many in the South and Southeast. The center's July 18 report shows at least 26 states plus Washington, D.C., are encountering a summer surge, according to its epidemic trend modeling, using data from emergency department visits. The CDC notes its modeling indicates trends in overall cases, not the actual numbers of current infections. New COVID variant is spreading: What are the symptoms? A familiar summer surge The rate of positive COVID-19 tests is increasing nationally, the CDC said of the last week in data, with emergency department visits for the virus are increasing among children 4 years old and younger. Though there is an uptick in COVID-19 cases in more than two dozen states, the CDC says the overall amount of people seeking care for acute respiratory illnesses is at a very low level. That's accompanied by low levels of seasonal influenza activity and very low levels of RSV activity, the CDC says. Overall, trends in COVID-19 cases continue downward as compared to the last few years, according to long-term data trends in deaths, emergency room visits and positive cases. The U.S. has seen a wave of higher COVID-19 cases every summer since 2020. COVID-19 in 2025: What's the latest vaccine guidance? It's complicated. COVID-19 cases are growing in 10 states: The CDC's latest report says cases are likely growing in more than a dozen other states, plus Washington, D.C. In one state − Montana − COVID-19 cases are likely declining. COVID-19 cases are likely growing in the following 16 states: Kathryn Palmer is a national trending news reporter for USA TODAY. You can reach her at kapalmer@ and on X @KathrynPlmr.
Medscape
2 hours ago
- Medscape
The Pandemic Literally Aged Our Brains
This transcript has been edited for clarity. Welcome to Impact Factor , your weekly dose of commentary on a new medical study. I'm Dr F. Perry Wilson from the Yale School of Medicine. Living through the COVID pandemic aged your brain by about five and a half extra months. This, according to new research. It's a pretty scary headline, but what does 'brain age' even mean, how do you measure it, and what risks does a five-and-a-half month older brain have to face? We're going to use what's left of our brains to dig through the data this week. Stay tuned. The study generating those scary headlines is 'Accelerated Brain Ageing During the COVID-19 Pandemic', from Ali-Reza Mohammadi-Nejad and colleagues, appearing in Nature Communications . But before we get into it, a reminder that SARS-CoV-2, the virus that caused the COVID-19 pandemic, is a weird one, especially when it comes to the brain. It was pretty early in the pandemic when we realized that one of the rather unique symptoms that came with COVID infection, differentiating it from the common cold and flu infections and the like, was anosmia — the loss of smell. It turned out this was due to infection of some epithelial cells in the nose, with inflammation impacting the olfactory bulb of the brain. To be clear, evidence of direct brain infection by SARS-CoV-2 is fairly weak. Neurons don't express high levels of the ACE2 receptor — the viruses' point of entry to other cells. And while some autopsy studies have found viral genetic material in the brain, it has been quite difficult to find live virus in brain cells. But secondary effects of the virus — inflammation and microclotting— do affect the brain. And multiplestudies have suggested that infection can worsen certain cognitive outcomes. There was more to the pandemic than just the virus, though. There was social isolation, higher levels of stress, and loss of work and other cognitively stimulating activities. In other words, there were lots of reasons for people's brains to get a little worse during those few years. That's really what the Nature Communications study is looking at. It's an overall sense of how our brains are doing, and 'brain age' is a useful proxy for that concept. So, what is brain age? It's pretty straightforward. Imagine a carnival barker doing the 'guess your age' thing. You come up, they take a look at you, squint, and call out a number, usually with startling accuracy. The carnival barker is using various clues — features on your face, wrinkles, hairstyle, and so on — to make a guess. We can do the same thing with an MRI machine. We just have to teach a computer what the brains of different ages look like. That's what researchers did here. Using the huge UK biobank cohort, they took brain scans of more than 15,000 healthy people of various ages and trained a machine-learning model to predict age based just on the images. It got pretty accurate, as you can see here. Of course, it's not perfect. Nor would we expect it to be. Some people's brains look younger than their stated age. Call it the Paul Rudd effect. And, of course, some brains look older than they should. The distance between your calendar age and your brain age is the 'brain age gap' (BAG), with higher numbers implying that your brain is older than it should be. This gap seems to stay pretty consistent over time. If your BAG is 5 years right now, it tends to stay around 5 years even a few years later, provided nothing intervenes to more rapidly age your brain. If anyone ever accuses you of having an excessive BAG, you can say 'that's not my bag, baby.' (And that ends the '90s references for this week.) It's the repeated brain scans that make this study interesting. The researchers identified about 1000 participants who had multiple brain scans, on average about 2 years apart. For 432 of those folks, the pandemic happened between the two scans. So, we can look at how much their brains aged in that timeframe and compare that aging to a group who was not exposed to the pandemic. This is the meat of the study. Here are the primary results. Remember, BAG is supposed to stay pretty stable if nothing else has changed. And that's what we see in the control group. Between the two scans, there was, on average, no change in BAG — though the distribution here encompasses changes in both directions. Now we add the pandemic group. What you see is that the distribution has shifted, on average by 5.5 months. That's where we get that headline that started this whole thing. But of course, 5.5 is just the average change in BAG. Different people's brains aged at different speeds. Still, overall, this is a statistically significant difference. You're probably wondering why some brains aged more than others. The 5.5 month result is the effect of the pandemic – not necessarily infection. Out of the 432 individuals with a postpandemic scan, 134 actually had documented COVID-19 before that second scan. Interestingly, the increase in brain age was similar among those infected and those not infected. To be fair, only five of those infected were sick enough to be hospitalized, but it still seems that the bulk of the aging effect of the pandemic may have been due to factors independent of the virus itself; factors that made the pandemic effect worse. The brains of older people and men seemed to age more during the pandemic than those of younger people and women. Poor socioeconomic status and lower education also led to more pandemic brain aging. Still, it's not how you look; it's how you feel. Do older-looking brains on brain scans function worse? The study doesn't offer much support for this. Cognitive testing found no compelling relationship between changes in brain age and changes in various tests of cognitive ability across the entire cohort. There did seem to be some relationship among those infected with COVID-19: They did worse on cognitive tests if their brains had aged more than expected. But I'm often wary of signals like this that appear in a very particular subgroup. Leaving the realm of data and stepping squarely into the land of speculation, I think what we are likely seeing here is that the pandemic was a population-wide neurologic stressor. The isolation, the anxiety, and the lack of cognitive stimulation led our brains to atrophy a bit. It does not seem that this is a direct result of viral infection, though again, we don't have data on people with more severe COVID-19. The big question is, what happens next? Now that we are reintegrated with society, back at work, and using our brains a bit more, will they grow younger again? It remains to be seen. But if the pandemic-induced gray in my hair is any indicator, there may be no going back.
Time Magazine
3 hours ago
- Time Magazine
COVID-19 Made Our Brains Age Faster
COVID-19 is leaving all kinds of legacies on our health, both on our bodies and our brains. In a study published July 22 in Nature Communications, researchers report that living through the pandemic aged our brains—whether or not you were infected with COVID-19. To investigate COVID-19's impact on the brain, researchers looked at brain scans from 1,000 people during and before the pandemic. They compared these to brain scans from other people taken during "normal" times as a model for typical brain aging. Led by Ali-Reza Mohammadi-Nejad from the University of Nottingham School of Medicine in the U.K., the researchers looked at measures like brain function, gray and white matter volume, a person's cognitive skills, and their chronological age. Gray matter is critical for memory, emotions, and movement, while white matter is essential for helping nerves transmit electrical signals. The pandemic-era brains aged about 5.5 months faster compared to the brains of those studied before the pandemic. The accelerated aging was documented in people who had COVID-19 infections as well as those who didn't, which strongly suggests that pandemic-related factors other than biological or virus-driven ones—like high stress—were also at work. In fact, the changes in gray and white matter were similar in people who were and were not infected. 'This finding was interesting and rather unexpected,' says Mohammadi-Nejad. Other studies have already shown that the COVID-19 virus can change the brain for the worse, but "we found that participants who simply lived through the pandemic period, regardless of infection, also showed signs of slightly accelerated brain aging. This highlights that the broader experience of the pandemic—including disruptions to daily life, stress, reduced social interactions, reduced activity, etc.,—may have had a measurable impact on brain health.' Read More: What to Know About the New COVID-19 Variant XFG The impact of the pandemic seemed to be greater in certain groups—notably men, the elderly, and people with more compromised health, lower educational status and income, or unstable housing. People with less stable employment had an average of five months of additional brain aging compared to those with higher employment status, while poorer health added about four months of increased brain age compared to better health. However, only people infected with COVID-19 showed drops in cognitive skills. But the fact that those who weren't infected during the pandemic also showed accelerated aging reflects the need to acknowledge the broader health effects of the pandemic beyond the obvious physical metrics on which doctors tend to focus. 'Brain health can be influenced by everyday life activities, and major societal disruptions—like those experienced during the pandemic—can leave a mark even in healthy individuals,' Mohammadi-Nejad says. 'This adds to our understanding of public health by reinforcing the importance of considering mental, cognitive, and social well-being alongside traditional physical health indicators during future crisis-response planning.' While the study did not explore specific ways to address brain aging, he says that strategies known to maintain brain health, such as a healthy diet, exercise, adequate sleep, and social and cognitive interactions are important, especially in the context of stressful circumstances such as a pandemic. 'Whether these can reverse the specific changes we observed remains to be studied,' he says.
